Arcellx, Inc. recently announced the FDA’s acceptance of the Biologics License Application (BLA) for its lead candidate anito-cel, a BCMA-targeting ddCAR therapy for relapsed or refractory multiple myeloma. This regulatory milestone coincides with Arcellx entering into a definitive merger agreement with Gilead Sciences, signaling strategic validation from a major industry player. The company’s proprietary cell therapy platforms—D-Domain, ddCAR, and ARC-SparX—position it distinctively within hematologic malignancy treatment, despite inherent clinical and regulatory risks. Financially, Arcellx maintains solid liquidity amidst rising operating losses, underpinning its near-term development and potential commercialization efforts.